190 related articles for article (PubMed ID: 35981368)
81. High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma.
Hou Y; Wang HQ; Ba Y
Med Oncol; 2012 Dec; 29(5):3498-503. PubMed ID: 22528513
[TBL] [Abstract][Full Text] [Related]
82. A Preliminary Study on Metadherin as a Potential Marker for Progression of Diffuse Large B Cell Lymphoma.
Ge X; Sui X; Fang X; Jiang Y; Ding M; Liu X; Wang X
Genet Test Mol Biomarkers; 2018 Aug; 22(8):481-486. PubMed ID: 30117777
[TBL] [Abstract][Full Text] [Related]
83. Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL).
Markovic O; Marisavljevic D; Cemerikic-Martinovic V; Martinovic T; Filipovic B; Stanisavljevic D; Zivković R; Hajder J; Stanisavljevic N; Mihaljevic B
Med Oncol; 2012 Dec; 29(5):3515-21. PubMed ID: 22528517
[TBL] [Abstract][Full Text] [Related]
84. Hypomethylation and the Resultant Overexpressed PARM1: a Biomarker for Poor Prognosis of Diffuse Large B-cell Lymphoma.
Cao B; Guo X; Wang B; Wang W; Han D; Zhang W; Zhong K
Discov Med; 2022; 33(168):27-40. PubMed ID: 36274211
[TBL] [Abstract][Full Text] [Related]
85.
Wu X; Li Y; Zhang W; Zhang J; Chen B; Ge Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552804
[TBL] [Abstract][Full Text] [Related]
86. A Novel Autophagy-Related Prognostic Risk Model and a Nomogram for Survival Prediction of Oral Cancer Patients.
Fei H; Chen X
Biomed Res Int; 2022; 2022():2067540. PubMed ID: 35036428
[TBL] [Abstract][Full Text] [Related]
87. Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B-cell lymphoma cells and their association with clinical features.
Kobayashi K; Yamaguchi M; Miyazaki K; Imai H; Yokoe K; Ono R; Nosaka T; Katayama N
Cancer Med; 2016 Aug; 5(8):1802-9. PubMed ID: 27184832
[TBL] [Abstract][Full Text] [Related]
88. Quantification and prognostic value of programmed cell death ligand-1 expression in dogs with diffuse large B-cell lymphoma.
Ambrosius LA; Dhawan D; Ramos-Vara JA; Ruple A; Knapp DW; Childress MO
Am J Vet Res; 2018 Jun; 79(6):643-649. PubMed ID: 30085860
[TBL] [Abstract][Full Text] [Related]
89. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas.
De Paepe P; Achten R; Verhoef G; Wlodarska I; Stul M; Vanhentenrijk V; Praet M; De Wolf-Peeters C
J Clin Oncol; 2005 Oct; 23(28):7060-8. PubMed ID: 16129841
[TBL] [Abstract][Full Text] [Related]
90. Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma.
Cao D; Cao X; Jiang Y; Xu J; Zheng Y; Kang D; Xu C
Hematol Oncol; 2022 Apr; 40(2):172-180. PubMed ID: 34874565
[TBL] [Abstract][Full Text] [Related]
91. Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms.
Yu H; Peng S; Han S; Chen X; Lyu Q; Lei T
Biomed Res Int; 2021; 2021():5514726. PubMed ID: 34250086
[TBL] [Abstract][Full Text] [Related]
92. Identification of three small nucleolar RNAs (snoRNAs) as potential prognostic markers in diffuse large B-cell lymphoma.
Li MW; Huang FX; Xie ZC; Hong HY; Xu QY; Peng ZG
Cancer Med; 2023 Feb; 12(3):3812-3829. PubMed ID: 36812125
[TBL] [Abstract][Full Text] [Related]
93. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
[TBL] [Abstract][Full Text] [Related]
94. TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.
Liu Y; Wang X; Ding N; Mi L; Ping L; Jin X; Li J; Xie Y; Ying Z; Liu W; Zhang C; Deng L; Song Y; Zhu J
BMC Cancer; 2017 Nov; 17(1):743. PubMed ID: 29126407
[TBL] [Abstract][Full Text] [Related]
95. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
Front Immunol; 2021; 12():732006. PubMed ID: 34745101
[TBL] [Abstract][Full Text] [Related]
96. Identification and Validation of a Prognostic Model Based on Three Autophagy-Related Genes in Hepatocellular Carcinoma.
Qin F; Zhang J; Gong J; Zhang W
Biomed Res Int; 2021; 2021():5564040. PubMed ID: 33778066
[TBL] [Abstract][Full Text] [Related]
97. [Comparison of Different Staging Systems and Prognostic Analysis in 68 Cases of Primary Intestinal Diffuse Large B Cell Lymphoma].
Wang X; Wang CY; Xu W; Yang HL; Zhao HF; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):52-60. PubMed ID: 30738447
[TBL] [Abstract][Full Text] [Related]
98. High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma.
Carreras J; Kikuti YY; Hiraiwa S; Miyaoka M; Tomita S; Ikoma H; Ito A; Kondo Y; Itoh J; Roncador G; Martinez A; Colomo L; Hamoudi R; Ando K; Nakamura N
Cancer Sci; 2022 Jan; 113(1):334-348. PubMed ID: 34706126
[TBL] [Abstract][Full Text] [Related]
99. [Prognosis analysis of primary breast diffuse large B cell lymphoma].
Zhu YH; Meng WJ; He LH; Jia YS; Tong ZS
Zhonghua Zhong Liu Za Zhi; 2019 Mar; 41(3):235-240. PubMed ID: 30917462
[No Abstract] [Full Text] [Related]
100. A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma.
Xu H; Li Y; Jiang Y; Wang J; Sun H; Wu W; Lv Y; Liu S; Zhai Y; Tian L; Li L; Zhao Z
Front Genet; 2022; 13():827840. PubMed ID: 35774514
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
